Wilson’s disease is a rare inherited metabolic disorder characterized by abnormal copper accumulation in the body, particularly in the liver, brain, and eyes. It occurs due to mutations that impair copper excretion, leading to progressive organ damage if left untreated. Early and accurate diagnosis is essential, as timely intervention can prevent irreversible complications and significantly improve patient outcomes.

Diagnosis of Wilson’s disease is challenging because its symptoms vary widely and often resemble other liver or neurological disorders. Patients may present with fatigue, jaundice, tremors, difficulty speaking, or behavioral changes. In younger individuals, liver-related symptoms are more common, while neurological and psychiatric manifestations tend to appear later.

A combination of clinical evaluation and laboratory testing is typically used to confirm diagnosis. Blood tests measuring ceruloplasmin levels, serum copper concentration, and liver enzymes provide important initial clues. Reduced ceruloplasmin levels are frequently observed, although they are not exclusive to Wilson’s disease.

Urinary copper excretion testing is another key diagnostic tool. Elevated copper levels in a 24-hour urine collection strongly support the diagnosis. Ophthalmologic examination using slit-lamp evaluation may reveal Kayser–Fleischer rings, which are copper deposits around the cornea and a characteristic sign of the disease.

In some cases, liver biopsy is performed to directly measure hepatic copper concentration. While invasive, this method offers definitive confirmation when other test results are inconclusive. Genetic testing has also become increasingly valuable, allowing identification of mutations responsible for the disorder.

Accurate diagnosis enables early treatment with copper-chelating agents or zinc therapy, preventing disease progression. Awareness among clinicians and improved diagnostic strategies continue to play a vital role in managing Wilson’s disease effectively.